Opioids

By Riley Stanton, CAFP Communications and Marketing Intern The manufacturers of opioid painkillers aggressively marketed their products in the 1990s, exaggerating the benefits and downplaying the risks, while simultaneously lobbying lawmakers to make it easier for patients to receive the drugs. Even as the rise in addictions, overdoses, and opioid-related deaths became apparent, the top

By Sarah Martinez, CAFP Policy & Advocacy Intern In October, the U.S. Senate passed the final version of H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. This act is a bipartisan bill package that aims to combat the opioid crisis. The President signed the bill